title: Spironolactone for resistant hypertension--hard to resist?
authors.affiliation: Department of Medicine, ASH Comprehensive Hypertension Center, Section of Endocrinology, Diabetes and Metabolism, University of Chicago, Chicago, IL 60637, USA.
authors.forename: Hillel
authors.initials: H
authors.lastname: Sternlicht
authors.affiliation: Department of Medicine, ASH Comprehensive Hypertension Center, Section of Endocrinology, Diabetes and Metabolism, University of Chicago, Chicago, IL 60637, USA. Electronic address: gbakris@gmail.com.
authors.forename: George L
authors.initials: GL
authors.lastname: Bakris
mesh_terms: D058668:Adrenergic alpha-1 Receptor Antagonists / Q000627:therapeutic use*; D058671:Adrenergic beta-1 Receptor Antagonists / Q000627:therapeutic use*; D017298:Bisoprolol / Q000627:therapeutic use*; D017292:Doxazosin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use*; D013148:Spironolactone / Q000627:therapeutic use*
chemical_list: D058668:Adrenergic alpha-1 Receptor Antagonists; D058671:Adrenergic beta-1 Receptor Antagonists; D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone; D017292:Doxazosin; D017298:Bisoprolol